| Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 … M Sholzberg, GH Tang, H Rahhal, M AlHamzah, LB Kreuziger, FN Áinle, ... bmj 375, 2021 | 341 | 2021 |
| Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial P Bégin, J Callum, E Jamula, R Cook, NM Heddle, A Tinmouth, MP Zeller, ... Nature medicine 27 (11), 2012-2024, 2021 | 259 | 2021 |
| Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial SZ Usmani, F Schjesvold, A Oriol, L Karlin, M Cavo, RM Rifkin, HA Yimer, ... The Lancet Haematology 6 (9), e448-e458, 2019 | 220 | 2019 |
| Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t (11; 14) C Touzeau, S Le Gouill, B Mahé, JS Boudreault, T Gastinne, N Blin, ... Haematologica 102 (3), e112, 2017 | 43 | 2017 |
| Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials JS Boudreault, C Touzeau, P Moreau Expert Review of Hematology 10 (3), 207-215, 2017 | 25 | 2017 |
| Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/− R) is an effective treatment with low toxicity in … B Tessoulin, P Thomare, E Delande, J Moynard, T Gastinne, A Moreau, ... Annals of hematology 96, 943-950, 2017 | 19 | 2017 |
| The role of SLAMF7 in multiple myeloma: impact on therapy JS Boudreault, C Touzeau, P Moreau Expert review of clinical immunology 13 (1), 67-75, 2017 | 14 | 2017 |
| Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study R LeBlanc, I Ahmad, R Terra, JS Boudreault, D Ogez, K Lamore, ... Bone Marrow Transplantation 57 (2), 252-260, 2022 | 11 | 2022 |
| Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites DA Stewart, JS Boudreault, B Maturi, D Boras, R Foley Current Oncology 25 (5), 300, 2018 | 11 | 2018 |
| Bendamustine-induced nephrogenic diabetes insipidus–A case report A Desjardins, V Le-Nguyen, L Turgeon-Mallette, C Vo, JS Boudreault, ... Journal of Oncology Pharmacy Practice 28 (1), 205-210, 2022 | 5 | 2022 |
| Mm-372 a Phase Iii, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (Mezivd) Versus Pomalidomide, Bortezomib, and Dexamethasone (Pvd) in Relapsed … PG Richardson, SN Badelita, B Besemer, JS Boudreault, JM Byun, ... Clinical Lymphoma Myeloma and Leukemia 23, S495-S496, 2023 | 3 | 2023 |
| Testing Mayo clinic’s new 20/20/20 risk model in another cohort of smoldering Myeloma patients: a retrospective study C Tessier, T Allard, JS Boudreault, R Kaedbey, V Éthier, F Fortin, M Pavic Current Oncology 28 (3), 2029-2039, 2021 | 3 | 2021 |
| Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments C Tessier, R Leblanc, J Roy, S Trudel, J Cote, M Lalancette, ... Blood 142, 3399, 2023 | 1 | 2023 |
| Canadian Retrospective Multicentric Study Comparing the Combination of Bortezomib, Cyclophosphamide and Dexamethasone (Cybord) Versus Bortezomib, Thalidomide and Dexamethasone … E Yamga, R Leblanc, JS Boudreault Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 1 | 2018 |
| Evaluation of subcutaneous rituximab administration impacts on Canadian systemic therapy suites D Stewart, J Boudreault, B Maturi, D Boras, R Foley Value in Health 21, S250, 2018 | 1 | 2018 |
| Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia C Tessier, R LeBlanc, J Roy, S Trudel, J Côté, M Lalancette, ... Cancer Medicine 13 (17), e70192, 2024 | | 2024 |
| Efficacy and Safety of Bendamustine-Rituximab as Frontline Therapy for Indolent Non-Hodgkin Lymphoma: A Real-World, Single-Center, Retrospective Study T Chan, JN Champagne, JS Boudreault Cureus 16 (8), 2024 | | 2024 |
| POSTER: MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in … PG Richardson, SN Badelita, B Besemer, JS Boudreault, JM Byun, ... Clinical Lymphoma Myeloma and Leukemia 23, S228, 2023 | | 2023 |
| Autologous Stem Cell Transplant for relapsed Peripheral T-cell lymphoma in a dialysis-dependent patient JN Champagne, A Tosikyan, A Veilleux, JS Boudreault Open Journal of Clinical and Medical Case Reports 9 (29), 472-476, 2023 | | 2023 |
| Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous … MÉ Plante, X Feng, JS Boudreault Leukemia & Lymphoma 64 (7), 1234-1242, 2023 | | 2023 |
